https://scholars.lib.ntu.edu.tw/handle/123456789/564098
標題: | A novel alpha iIb beta 3 antagonist from snake venom prevents thrombosis without causing bleeding | 作者: | Kuo Y.-J. Chung C.-H. Pan T.-Y. Chuang W.-J. TUR-FU HUANG |
關鍵字: | Antiplatelet agent; Arterial thrombosis; Bleeding side effect; Disintegrins; Integrin αIIbβ3; Snake venom proteins | 公開日期: | 2019 | 卷: | 12 | 期: | 1 | 起(迄)頁: | 11 | 來源出版物: | Toxins | 摘要: | Life-threatening thrombocytopenia and bleeding, common side effects of clinically available αIIbβ3 antagonists, are associated with the induction of ligand-induced integrin conformational changes and exposure of ligand-induced binding sites (LIBSs). To address this issue, we examined intrinsic mechanisms and structure-activity relationships of purified disintegrins, from Protobothrops flavoviridis venom (i.e., Trimeresurus flavoviridis), TFV-1 and TFV-3 with distinctly different pro-hemorrhagic tendencies. TFV-1 with a different αIIbβ3 binding epitope from that of TFV-3 and chimeric 7 × 103 Fab, i.e., Abciximab, decelerates αIIbβ33 ligation without causing a conformational change in αIIbβ3, as determined with the LIBS antibody, AP5, and the mimetic, drug-dependent antibody (DDAb), AP2, an inhibitory monoclonal antibody raised against αIIbβ33. Consistent with their different binding epitopes, a combination of TFV-1 and AP2 did not induce FcγRIIa-mediated activation of the ITAM-Syk-PLCγ2 pathway and platelet aggregation, in contrast to the clinical antithrombotics, abciximab, eptifibatide, and disintegrin TFV-3. Furthermore, TFV-1 selectively inhibits Gα13-mediated platelet aggregation without affecting talin-driven clot firmness, which is responsible for physiological hemostatic processes. At equally efficacious antithrombotic dosages, TFV-1 caused neither severe thrombocytopenia nor bleeding in FcγRIIa-transgenic mice. Likewise, it did not induce hypocoagulation in human whole blood in the rotational thromboelastometry (ROTEM) assay used in perioperative situations. In contrast, TFV-3 and eptifibatide exhibited all of these hemostatic effects. Thus, the αIIbβ3 antagonist, TFV-1, efficaciously prevents arterial thrombosis without adversely affecting hemostasis. ? 2019 by the authors. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/564098 | ISSN: | 20726651 | DOI: | 10.3390/toxins12010011 | SDG/關鍵字: | abciximab; adenine nucleotide translocase; adenosine diphosphate; alpha2 integrin; collagen; disintegrin; eptifibatide; G protein coupled receptor; L selectin; monoclonal antibody; monoclonal antibody ap2; PADGEM protein; snake venom; tetrapeptide; thrombin; Trimeresurus ?avoviridis venom 1; Trimeresurus ?avoviridis venom 3; unclassified drug; abciximab; antithrombocytic agent; disintegrin; epitope; fibrinogen receptor; fibrinolytic agent; snake venom; animal experiment; animal model; Article; binding site; bleeding; bleeding time; blood clotting; blood clotting time; chromatography; column chromatography; controlled study; flow cytometry; gene sequence; hemostasis; high performance liquid chromatography; human; IC50; immunoprecipitation; ligand binding; liquid chromatography; mass spectrometry; matrix assisted laser desorption ionization time of flight mass spectrometry; mouse; nonhuman; pharmacokinetic parameters; platelet count; polyacrylamide gel electrophoresis; protein phosphorylation; Protobothrops ?avoviridis; reversed phase high performance liquid chromatography; structure activity relation; suicide; tandem mass spectrometry; thrombocyte activation; thrombocyte aggregation; thrombocyte function; thrombocyte rich plasma; thrombocytopenia; thrombosis; Western blotting; animal; bleeding; Institute for Cancer Research mouse; male; Trimeresurus; Abciximab; Animals; Binding Sites; Bleeding Time; Disintegrins; Epitopes; Fibrinolytic Agents; Hemorrhage; Humans; Male; Mice; Mice, Inbred ICR; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Snake Venoms; Structure-Activity Relationship; Trimeresurus |
顯示於: | 藥理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。